Vernazza et al., 1996 - Google Patents
High Seroprevalence of Parvovirus B19 among Patients Infected with Human Immunodeficiency Virus [with Reply]Vernazza et al., 1996
View PDF- Document ID
- 8574827317312902146
- Author
- Vernazza P
- Pfister L
- Siegl G
- Cassinotti P
- Dubin G
- Chernak E
- Friedman H
- Publication year
- Publication venue
- Clinical infectious diseases
External Links
Snippet
High Seroprevalence of Parvovirus B19 among Patients Infected with Human Immunodeficiency
Virus [with Reply] Page 1 198 Correspondence CID 1996;22 (January) Cerebral Mucormycosis
Associated with Intraveno Drug Use SIR-We want to add an important clinical point to the …
- 241000702617 Human parvovirus B19 0 title description 10
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/02—Medicinal preparations containing materials or reaction products thereof with undetermined constitution from inanimate materials
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/66—Micro-organisms or materials therefrom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/162—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from virus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/43—Enzymes; Proenzymes; Derivatives thereof
- A61K38/46—Hydrolases (3)
- A61K38/50—Hydrolases (3) acting on carbon-nitrogen bonds, other than peptide bonds (3.5), e.g. asparaginase
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/19—Cytokines; Lymphokines; Interferons
- A61K38/21—Interferons [IFN]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
Similar Documents
Publication | Publication Date | Title |
---|---|---|
Thorley-Lawson | The transformation of adult but not newborn human lymphocytes by Epstein Barr virus and phytohemagglutinin is inhibited by interferon: the early suppression by T cells of Epstein Barr infection is mediated by interferon. | |
Cohen et al. | Recent advances in varicella-zoster virus infection | |
JORDAN et al. | Spontaneous cytomegalovirus mononucleosis: clinical and laboratory observations in nine cases | |
COREY et al. | Intravenous acyclovir for the treatment of primary genital herpes | |
Guo et al. | Demonstration of the anti-viral activity of garlic extract against human cytomegalovirus in vitro | |
Bader et al. | The natural history of recurrent facial-oral infection with herpes simplex virus | |
Erlich et al. | Foscarnet therapy for severe acyclovir-resistant herpes simplex virus type-2 infections in patients with the acquired immunodeficiency syndrome (AIDS) an uncontrolled trial | |
Pettersson et al. | Prophylactic oral acyclovir after renal transplantation | |
Operskalski et al. | Blood donations and viruses | |
Obeagu et al. | Immunodeficiency and immune reconstitution in pediatric HIV: mechanisms, challenges, and therapeutic strategies | |
Wald et al. | A randomized, double-blind, comparative trial comparing high-and standard-dose oral acyclovir for first-episode genital herpes infections | |
Vernazza et al. | High Seroprevalence of Parvovirus B19 among Patients Infected with Human Immunodeficiency Virus [with Reply] | |
Blondeau et al. | Stress-induced reactivation of latent herpes simplex virus infection in rat lumbar dorsal root ganglia | |
Virol | Virus (Echovirus-12) in Drinking Water | |
Morales et al. | A seroepidemiologic study of hepatitis A in Spanish children. Relationship of prevalence to age and socio-environmental factors | |
Fowler | Viral infections | |
US4663317A (en) | Methods and compositions for treating viral infections | |
Barzoki et al. | In vitro evaluation of antiviral activity of Shouchella clausii probiotic strain and bacterial supernatant against herpes simplex virus type 1 | |
Haberthur et al. | Genome-wide analysis of T cell responses during acute and latent simian varicella virus infections in rhesus macaques | |
Knox et al. | Alteration of the growth of cytomegalovirus and herpes simplex virus type 1 by epidermal growth factor, a contaminant of crude human chorionic gonadotropin preparations. | |
Felsenfeld et al. | Phosphonoacetic acid in the treatment of simian varicella | |
Schinazi et al. | Antiviral activity of 5-ethyl-2'-deoxyuridine against herpes simplex viruses in cell culture, mice, and guinea pigs | |
Benjavongkulchai et al. | An immunogenicity and efficacy study of purified chick embryo cell culture rabies vaccine manufactured in Japan | |
Honda et al. | Effect of long-term, low-dose acyclovir suppressive therapy on susceptibility to acyclovir and frequency of acyclovir resistance of herpes simplex virus type 2 | |
Shope et al. | Fatal Encephalitis Due to Herpesvirus hominis: Use of Intact Brain Cells' for Isolation of Virus |